Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France.

NCT05813964 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

524

Enrollment

OTHER_GOV

Sponsor class

Conditions

HIV/AIDS

Interventions

DRUG: TDF/FTC 300mg/200mg fixed-dose combination tablets
DRUG: TAF/FTC 25mg/200mg fixed-dose combination tablets

Sponsor

ANRS, Emerging Infectious Diseases

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]